Identifying de‐NEDDylation inhibitors: Virtual high‐throughput screens targeting SENP8
暂无分享,去创建一个
Jonathan J. Chen | Lyndsey N. Schmucker | Jonathan J Chen | Lyndsey N Schmucker | Donald P Visco | D. Visco
[1] A. Ciechanover,et al. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. , 2002, Physiological reviews.
[2] Jean-Loup Faulon,et al. The Signature Molecular Descriptor. 1. Using Extended Valence Sequences in QSAR and QSPR Studies , 2003, J. Chem. Inf. Comput. Sci..
[3] Yi Sun,et al. The Nedd8-activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth. , 2012, Cancer research.
[4] Heng Tao Shen,et al. Principal Component Analysis , 2009, Encyclopedia of Biometrics.
[5] Shelly C. Lu,et al. Murine double minute 2 regulates Hu antigen R stability in human liver and colon cancer through NEDDylation , 2012, Hepatology.
[6] Junmei Wang,et al. Development and testing of a general amber force field , 2004, J. Comput. Chem..
[7] Jean-Loup Faulon,et al. Predicting protein-protein interactions using signature products , 2005, Bioinform..
[8] Gang Fu,et al. PubChem Substance and Compound databases , 2015, Nucleic Acids Res..
[9] J Andrew McCammon,et al. Protein flexibility and computer-aided drug design. , 2003, Annual review of pharmacology and toxicology.
[10] B. Blagoev,et al. Systematic in vivo RNAi analysis identifies IAPs as NEDD8-E3 ligases. , 2010, Molecular cell.
[11] D. Lane,et al. Mdm2-Mediated NEDD8 Conjugation of p53 Inhibits Its Transcriptional Activity , 2004, Cell.
[12] F. Z. Watts,et al. Nep1, a Schizosaccharomyces pombe deneddylating enzyme. , 2005, The Biochemical journal.
[13] M. Hochstrasser,et al. Evolution and function of ubiquitin-like protein-conjugation systems , 2000, Nature Cell Biology.
[14] Jean-Loup Faulon,et al. The signature molecular descriptor. 3. Inverse-quantitative structure-activity relationship of ICAM-1 inhibitory peptides. , 2003, Journal of molecular graphics & modelling.
[15] V. D. da Silva,et al. Computer-aided drug design and ADMET predictions for identification and evaluation of novel potential farnesyltransferase inhibitors in cancer therapy. , 2010, Journal of molecular graphics & modelling.
[16] Jonathan J. Chen,et al. Developing an in silico pipeline for faster drug candidate discovery: Virtual high throughput screening with the Signature molecular descriptor using support vector machine models , 2017 .
[17] E. Campbell,et al. Central Role for Endothelial Human Deneddylase-1/SENP8 in Fine-Tuning the Vascular Inflammatory Response , 2013, The Journal of Immunology.
[18] Jacob D. Durrant,et al. Molecular dynamics simulations and drug discovery , 2011, BMC Biology.
[19] Jacob D. Durrant,et al. Computer-aided drug-discovery techniques that account for receptor flexibility. , 2010, Current opinion in pharmacology.
[20] D. Pereira,et al. Origin and evolution of high throughput screening , 2007, British journal of pharmacology.
[21] Jean-Loup Faulon,et al. Stochastic Generator of Chemical Structure. 1. Application to the Structure Elucidation of Large Molecules , 1994, Journal of chemical information and computer sciences.
[22] Jean-Loup Faulon,et al. Data mining PubChem using a support vector machine with the Signature molecular descriptor: classification of factor XIa inhibitors. , 2008, Journal of molecular graphics & modelling.
[23] Anindya Dutta,et al. NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. , 2010, Cancer research.
[24] R. Hay,et al. NEDP1, a Highly Conserved Cysteine Protease That deNEDDylates Cullins* , 2003, Journal of Biological Chemistry.
[25] E. Yeh,et al. Neddylation of a breast cancer-associated protein recruits a class III histone deacetylase that represses NFκB-dependent transcription , 2006, Nature Cell Biology.
[26] Jinfang Zhang,et al. hCINAP is a novel regulator of ribosomal protein-HDM2-p53 pathway by controlling NEDDylation of ribosomal protein S14 , 2014, Oncogene.
[27] Jean-Loup Faulon,et al. Developing a methodology for an inverse quantitative structure-activity relationship using the signature molecular descriptor. , 2002, Journal of molecular graphics & modelling.
[28] Mario R. Eden,et al. Reverse problem formulation approach to molecular design using property operators based on signature descriptors , 2010, Comput. Chem. Eng..
[29] Shi-Chung Chang,et al. The Molecular Determinants of NEDD8 Specific Recognition by Human SENP8 , 2011, PloS one.
[30] Ruben Abagyan,et al. A natural product-like inhibitor of NEDD8-activating enzyme. , 2011, Chemical communications.
[31] Corinna Cortes,et al. Support-Vector Networks , 1995, Machine Learning.
[32] Luming Yin,et al. Identification and Characterization of DEN1, a Deneddylase of the ULP Family* , 2003, Journal of Biological Chemistry.
[33] W. Guida,et al. The art and practice of structure‐based drug design: A molecular modeling perspective , 1996, Medicinal research reviews.
[34] Vikrant A. Dev,et al. Structure Generation of Candidate Reactants Using Signature Descriptors , 2014 .
[35] Yanli Wang,et al. PubChem BioAssay: 2014 update , 2013, Nucleic Acids Res..
[36] Kurt Hornik,et al. kernlab - An S4 Package for Kernel Methods in R , 2004 .
[37] Keiji Tanaka,et al. The NEDD8 system is essential for cell cycle progression and morphogenetic pathway in mice , 2001, The Journal of cell biology.
[38] Bhuvanesh Singh,et al. SCCRO (DCUN1D1) Promotes Nuclear Translocation and Assembly of the Neddylation E3 Complex* , 2011, The Journal of Biological Chemistry.
[39] N. Chemmangattuvalappil,et al. A Novel Methodology for Property-Based Molecular Design Using Multiple Topological Indices , 2013 .
[40] Matthew L. Danielson,et al. Computer-aided drug design platform using PyMOL , 2011, J. Comput. Aided Mol. Des..
[41] Zongwei Li,et al. The multifaceted regulation and functions of PKM2 in tumor progression. , 2014, Biochimica et biophysica acta.
[42] B. Delaval,et al. The use of the NEDD8 inhibitor MLN4924 (Pevonedistat) in a cyclotherapy approach to protect wild-type p53 cells from MLN4924 induced toxicity , 2016, Scientific Reports.
[43] Darrell Whitley,et al. A genetic algorithm tutorial , 1994, Statistics and Computing.
[44] Yun He,et al. Learning from the Data: Mining of Large High-Throughput Screening Databases , 2006, J. Chem. Inf. Model..
[45] Jonathan J. Chen,et al. Pharmaceutical Machine Learning: Virtual High-Throughput Screens Identifying Promising and Economical Small Molecule Inhibitors of Complement Factor C1s , 2018, Biomolecules.
[46] M. Roussel,et al. E2-RING expansion of the NEDD8 cascade confers specificity to cullin modification. , 2009, Molecular cell.
[47] G. Morgan,et al. Bortezomib (Velcade™) in the Treatment of Multiple Myeloma , 2006, Therapeutics and clinical risk management.
[48] M. Dasso,et al. Modification in reverse: the SUMO proteases. , 2007, Trends in biochemical sciences.
[49] Ola Spjuth,et al. Ligand-Based Target Prediction with Signature Fingerprints , 2014, J. Chem. Inf. Model..
[50] W. Gu,et al. FBXO11 Promotes the Neddylation of p53 and Inhibits Its Transcriptional Activity* , 2007, Journal of Biological Chemistry.
[51] Dik-Lung Ma,et al. Discovery of a natural product inhibitor targeting protein neddylation by structure-based virtual screening. , 2012, Biochimie.
[52] G. Labesse,et al. LEA3D: a computer-aided ligand design for structure-based drug design. , 2005, Journal of medicinal chemistry.
[53] C. Chien,et al. DEN1 deneddylates non-cullin proteins in vivo , 2008, Journal of Cell Science.
[54] L. Jeong,et al. Targeting protein neddylation with an NEDD8-activating enzyme inhibitor MLN4924 induced apoptosis or senescence in human lymphoma cells , 2015, Cancer biology & therapy.
[55] I. Sumara,et al. The human Dcn1-like protein DCNL3 promotes Cul3 neddylation at membranes , 2009, Proceedings of the National Academy of Sciences.
[56] John J. Irwin,et al. ZINC 15 – Ligand Discovery for Everyone , 2015, J. Chem. Inf. Model..
[57] N. Wei,et al. DEN1 Is a Dual Function Protease Capable of Processing the C Terminus of Nedd8 and Deconjugating Hyper-neddylated CUL1* , 2003, Journal of Biological Chemistry.
[58] Y. Gotoh,et al. NEDDylation controls the target specificity of E2F1 and apoptosis induction , 2013, Oncogene.
[59] M. Ohh,et al. Mdm2-mediated NEDD8 Modification of TAp73 Regulates Its Transactivation Function* , 2006, Journal of Biological Chemistry.
[60] T. Toda,et al. Covalent modifier NEDD8 is essential for SCF ubiquitin‐ligase in fission yeast , 2000, The EMBO journal.
[61] Luca Scrucca,et al. GA: A Package for Genetic Algorithms in R , 2013 .
[62] B. Mahata,et al. Recruitment of RPL11 at promoter sites of p53-regulated genes upon nucleolar stress through NEDD8 and in an Mdm2-dependent manner , 2012, Oncogene.
[63] John P. Overington,et al. ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..
[64] Jean-Loup Faulon,et al. The Signature Molecular Descriptor. 2. Enumerating Molecules from Their Extended Valence Sequences , 2003, J. Chem. Inf. Comput. Sci..
[65] S. Jentsch,et al. A novel protein modification pathway related to the ubiquitin system , 1998, The EMBO journal.
[66] Andreas Bender,et al. Similarity Searching of Chemical Databases Using Atom Environment Descriptors (MOLPRINT 2D): Evaluation of Performance , 2004, J. Chem. Inf. Model..
[67] H. Kawasaki,et al. A new NEDD8-ligating system for cullin-4A. , 1998, Genes & development.
[68] Ola Spjuth,et al. Benchmarking Study of Parameter Variation When Using Signature Fingerprints Together with Support Vector Machines , 2014, J. Chem. Inf. Model..
[69] A. Nakashima,et al. X‐linked inhibitor of apoptosis protein mediates neddylation by itself but does not function as a NEDD8–E3 ligase for caspase‐7 , 2012, FEBS letters.
[70] Yi Sun,et al. Neddylation inhibitor MLN4924 suppresses growth and migration of human gastric cancer cells , 2016, Scientific Reports.
[71] J. Baell,et al. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.
[72] Amanda Doucette,et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer , 2009, Nature.
[73] M. Goebl,et al. Modification of yeast Cdc53p by the ubiquitin-related protein rub1p affects function of the SCFCdc4 complex. , 1998, Genes & development.
[74] J. Mccammon,et al. Accounting for Receptor Flexibility and Enhanced Sampling Methods in Computer‐Aided Drug Design , 2013, Chemical biology & drug design.
[75] Jun Du,et al. c-Cbl-mediated neddylation antagonizes ubiquitination and degradation of the TGF-β type II receptor. , 2013, Molecular cell.
[76] C. Dobson. Chemical space and biology , 2004, Nature.
[77] J. Drews. Drug discovery: a historical perspective. , 2000, Science.
[78] Chao Ning,et al. Performance Gains in Genome-Wide Association Studies for Longitudinal Traits via Modeling Time-varied effects , 2017, Scientific Reports.
[79] D. Triggle. Drug Discovery and Delivery in the 21st Century , 2006, Medical Principles and Practice.
[80] Richard Pazdur,et al. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. , 2003, The oncologist.
[81] Geng-Hung Liu,et al. NEDDylation regulates E2F‐1‐dependent transcription , 2012, EMBO reports.
[82] Yanli Wang,et al. Structure-Based Virtual Screening for Drug Discovery: a Problem-Centric Review , 2012, The AAPS Journal.
[83] Qiang Hu,et al. Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo. , 2016, Blood.
[84] Huahui Zeng,et al. Alzheimer's disease drug development based on Computer-Aided Drug Design. , 2016, European journal of medicinal chemistry.
[85] M. Estelle,et al. The ubiquitin-related protein RUB1 and auxin response in Arabidopsis. , 1998, Science.
[86] R. Barandelaa,et al. Strategies for learning in class imbalance problems , 2003, Pattern Recognit..
[87] Jonathan J. Chen,et al. Identifying novel factor XIIa inhibitors with PCA-GA-SVM developed vHTS models. , 2017, European journal of medicinal chemistry.
[88] John H. Van Drie,et al. Computer-aided drug design: the next 20 years , 2007, J. Comput. Aided Mol. Des..
[89] Hamed M. Kayello,et al. An Application of Computer‐Aided Molecular Design (CAMD) Using the Signature Molecular Descriptor—Part 1. Identification of Surface Tension Reducing Agents and the Search for Shrinkage Reducing Admixtures , 2014 .
[90] Donald P. Visco,et al. Computer-aided molecular design using the Signature molecular descriptor: Application to solvent selection , 2010, Comput. Chem. Eng..
[91] Yi-Ping Phoebe Chen,et al. Structure-based drug design to augment hit discovery. , 2011, Drug discovery today.
[92] Lingqiang Zhang,et al. MLN4924 (Pevonedistat), a protein neddylation inhibitor, suppresses proliferation and migration of human clear cell renal cell carcinoma , 2017, Scientific Reports.
[93] Yi Pan,et al. HybridDock: A Hybrid Protein-Ligand Docking Protocol Integrating Protein- and Ligand-Based Approaches , 2016, J. Chem. Inf. Model..
[94] P. Kollman,et al. A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules , 1995 .
[95] Derick C. Weis,et al. The Signature Molecular Descriptor. 5. The Design of Hydrofluoroether Foam Blowing Agents Using Inverse-QSAR , 2005 .
[96] Xin Chen,et al. Performance of Similarity Measures in 2D Fragment-Based Similarity Searching: Comparison of Structural Descriptors and Similarity Coefficients , 2002, J. Chem. Inf. Comput. Sci..
[97] T. Robak. Bortezomib in the treatment of mantle cell lymphoma. , 2015, Future oncology.
[98] M. Ohh,et al. Chemotherapy induces NEDP1-mediated destabilization of MDM2 , 2010, Oncogene.